We are thankful to the authors for providing us with a comprehensive metaanalysis that increases all clinicians’ confidence in further evaluating the role of DOACs in the therapy of LVT. We also note that treatment with these agents is much easier to manage both for the patient and clinician and are generally associated with much less clinically relevant bleeding. We congratulate the authors for taking a major step in defining the role of DOACs in patients with LVT. Their metaanalysis should serve as a background for a larger randomized controlled trial to evaluate efficacy and safety of DOACs in the treatment of patients with LVT.
ASJC Scopus subject areas
- Internal Medicine